全文获取类型
收费全文 | 2901篇 |
免费 | 218篇 |
国内免费 | 18篇 |
专业分类
耳鼻咽喉 | 28篇 |
儿科学 | 118篇 |
妇产科学 | 38篇 |
基础医学 | 543篇 |
口腔科学 | 39篇 |
临床医学 | 313篇 |
内科学 | 603篇 |
皮肤病学 | 21篇 |
神经病学 | 240篇 |
特种医学 | 198篇 |
外科学 | 361篇 |
综合类 | 77篇 |
一般理论 | 2篇 |
预防医学 | 145篇 |
眼科学 | 64篇 |
药学 | 190篇 |
中国医学 | 6篇 |
肿瘤学 | 151篇 |
出版年
2021年 | 30篇 |
2020年 | 22篇 |
2019年 | 44篇 |
2018年 | 43篇 |
2017年 | 56篇 |
2016年 | 41篇 |
2015年 | 49篇 |
2014年 | 64篇 |
2013年 | 83篇 |
2012年 | 140篇 |
2011年 | 144篇 |
2010年 | 92篇 |
2009年 | 73篇 |
2008年 | 122篇 |
2007年 | 128篇 |
2006年 | 121篇 |
2005年 | 101篇 |
2004年 | 74篇 |
2003年 | 110篇 |
2002年 | 84篇 |
2001年 | 80篇 |
2000年 | 100篇 |
1999年 | 107篇 |
1998年 | 46篇 |
1997年 | 51篇 |
1996年 | 60篇 |
1995年 | 36篇 |
1994年 | 50篇 |
1993年 | 24篇 |
1992年 | 67篇 |
1991年 | 53篇 |
1990年 | 41篇 |
1989年 | 57篇 |
1988年 | 51篇 |
1987年 | 44篇 |
1986年 | 51篇 |
1985年 | 50篇 |
1984年 | 29篇 |
1983年 | 35篇 |
1981年 | 24篇 |
1980年 | 22篇 |
1979年 | 27篇 |
1978年 | 30篇 |
1976年 | 21篇 |
1975年 | 31篇 |
1973年 | 20篇 |
1972年 | 20篇 |
1971年 | 21篇 |
1970年 | 25篇 |
1932年 | 20篇 |
排序方式: 共有3137条查询结果,搜索用时 15 毫秒
61.
Beyond immune checkpoint blockade: New approaches to targeting host–tumor interactions in prostate cancer: Report from the 2014 Coffey–Holden prostate cancer Academy meeting 下载免费PDF全文
62.
A sensitive and precise radioreceptor assay for determining plasma levels of human factor VIII/von Willebrand's factor (FVIII/vWF) has been developed by taking advantage of the FVIII/vWF receptor sites on human platelets. Paraformaldehyde-fixed platelets, which were processed and then stored, retained FVIII/vWF binding activity and therefore could be used as a convenient source of receptors. The human plasma samples to be tested were initially filtered on 4% agarose columns to concentrate the FVIII/vWF protein in the void volume and to remove the factor(s) that interferes with the assay. The percent recovery of FVIII/vWF in the pooled eluent was measured by the recovery of added trace 125I-FVIII/vWF. The coefficients of intra- and interassay variation were 6% and 10%, respectively. The plasma FVIII/vWF concentrations determined by the assay for pooled normal plasma, hemophilia A plasma, and plasmas from two patients with von Willebrand's disease were 16.3 +/- 0.5, 52.6 +/- 1.5, 6.8 +/- 0.8, and 3.2 +/- 0.2 microgram/ml, respectively. The range of plasma FVIII/vWF concentrations varied between 8.3 microgram/ml and 24.9 microgram/ml for 10 normal adults. The plasma FVIII/vWF concentrations determined by the radioreceptor assay correlated well with levels measured by the ristocetin-induced platelet aggregation method, thus demonstrating the functional relevancy of the radioreceptor assay for plasma FVIII/vWF. 相似文献
63.
64.
Ivan Prokudin Cas Simons John R Grigg Rebecca Storen Vikrant Kumar Zai Y Phua James Smith Maree Flaherty Sonia Davila Robyn V Jamieson 《European journal of human genetics : EJHG》2014,22(7):907-915
Developmental eye diseases, including cataract/microcornea, Peters anomaly and coloboma/microphthalmia/anophthalmia, are caused by mutations encoding many different signalling and structural proteins in the developing eye. All modes of Mendelian inheritance occur and many are sporadic cases, so provision of accurate recurrence risk information for families and affected individuals is highly challenging. Extreme genetic heterogeneity renders testing for all known disease genes clinically unavailable with traditional methods. We used whole-exome sequencing in 11 unrelated developmental eye disease patients, as it provides a strategy for assessment of multiple disease genes simultaneously. We identified five causative variants in four patients in four different disease genes, GJA8, CRYGC, PAX6 and CYP1B1. This detection rate (36%) is high for a group of patients where clinical testing is frequently not undertaken due to lack of availability and cost. The results affected clinical management in all cases. These variants were detected in the cataract/microcornea and Peters anomaly patients. In two patients with coloboma/microphthalmia, variants in ABCB6 and GDF3 were identified with incomplete penetrance, highlighting the complex inheritance pattern associated with this phenotype. In the coloboma/microphthalmia patients, four other variants were identified in CYP1B1, and CYP1B1 emerged as a candidate gene to be considered as a modifier in coloboma/microphthalmia. 相似文献
65.
Pei-Yu Chen Lingfeng Qin Zhen W. Zhuang George Tellides Irit Lax Joseph Schlessinger Michael Simons 《Proceedings of the National Academy of Sciences of the United States of America》2014,111(15):5514-5519
Vascular endothelial growth factors (VEGFs) signal via their cognate receptor tyrosine kinases designated VEGFR1-3. We report that the docking protein fibroblast growth factor receptor substrate 2 (FRS2α) plays a critical role in cell signaling via these receptors. In vitro FRS2α regulates VEGF-A and VEGF-C–dependent activation of extracellular signal-regulated receptor kinase signaling and blood and lymphatic endothelial cells migration and proliferation. In vivo endothelial-specific deletion of FRS2α results in the profound impairment of postnatal vascular development and adult angiogenesis, lymphangiogenesis, and arteriogenesis. We conclude that FRS2α is a previously unidentified component of VEGF receptors signaling.Vascular endothelial growth factors (VEGFs) are key regulators of blood and lymphatic vessel development and homeostasis. The absence of VEGF-A during development results in a complete failure of blood vasculature formation (1), whereas VEGF-C knockout abolishes lymphangiogenesis (2). Both VEGF-A and VEGF-C play equally critical roles in postnatal formation and maintenance of various blood and lymphatic vessel beds (3–6). The two VEGFs signal via, respectively, the two receptor tyrosine kinases (RTK) VEGFR2 and VEGFR3 with the former primarily expressed in the arterial and venous vasculature and the latter in the lymphatic vasculature in adult tissues (7). The other VEGF receptor, VEGFR1, is thought to function largely as a “decoy” receptor in endothelial cells but can transmit signaling in mononuclear cells (7).All VEGF receptors share a number of structural similarities including an extracellular ligand binding domain, a single transmembrane region, and a cytoplasmic domain containing a tyrosine kinase domain with an insert region. Receptor activation requires ligand-induced dimerization that results in autophosphorylation of cytoplasmic tyrosines that serve as binding sites for various signaling proteins. In the case of VEGF-A receptor, VEGFR2 phosphorylation of Y1054/Y1059 is required for maximal VEGFR2 kinase activity that leads to phosphorylation of Y1175 (a phospholipase Cγ1 binding site also required for ERK activation) and Y951 (a TSAd binding site leading to Src activation) among others (7). VEGF-C signals via VEGFR3 in a similar manner.In the course of studying fibroblast growth factor (FGF) signaling, we noticed that an endothelial knockdown or deletion of a scaffold protein FRS2α, known to be involved in FGF and neural growth factor (NGF) receptor signaling (8–10), also affects VEGF signaling. FRS2α is a docking protein that contains an N-terminal myristylation site, a PTB domain, and a large C-terminal tail that contains four binding sites for the SH2 domain of the adaptor protein Grb2 and two binding sites for the SH2 domain of the tyrosine phosphatase Shp2 (11). Tyrosine phosphorylation of FRS2α at these binding sites leads to activation of MAPK signaling (12).In this study, we found that FRS2α plays a central role in regulation of VEGF signaling in blood and lymphatic endothelial cells. Its deletion profoundly reduced VEGF signaling in vitro and in vivo and resulted in impairment of postnatal vascular development and adult angiogenesis, lymphangiogenesis, and arteriogenesis. 相似文献
66.
Nils Schweingruber Henrike J. Fischer Lisa Fischer Jens van den Brandt Anna Karabinskaya Verena Labi Andreas Villunger Benedikt Kretzschmar Peter Huppke Mikael Simons Jan P. Tuckermann Alexander Flügel Fred Lühder Holger M. Reichardt 《Acta neuropathologica》2014,127(5):713-729
Glucocorticoids (GCs) are the standard therapy for treating multiple sclerosis (MS) patients suffering from an acute relapse. One of the main mechanisms of GC action is held to be the induction of T cell apoptosis leading to reduced lymphocyte infiltration into the CNS, yet our analysis of experimental autoimmune encephalomyelitis (EAE) in three different strains of genetically manipulated mice has revealed that the induction of T cell apoptosis is not essential for the therapeutic efficacy of GCs. Instead, we identified the redirection of T cell migration in response to chemokines as a new therapeutic principle of GC action. GCs inhibited the migration of T cells towards CCL19 while they enhanced their responsiveness towards CXCL12. Importantly, blocking CXCR4 signaling in vivo by applying Plerixafor® strongly impaired the capacity of GCs to interfere with EAE, as revealed by an aggravated disease course, more pronounced CNS infiltration and a more dispersed distribution of the infiltrating T cells throughout the parenchyma. Our observation that T cells lacking the GC receptor were refractory to CXCL12 further underscores the importance of this pathway for the treatment of EAE by GCs. Importantly, methylprednisolone pulse therapy strongly increased the capacity of peripheral blood T cells from MS patients of different subtypes to migrate towards CXCL12. This indicates that modulation of T cell migration is an important mechanistic principle responsible for the efficacy of high-dose GC therapy not only of EAE but also of MS. 相似文献
67.
68.
69.
70.
PJ Hurley L Marchionni BW Simons AE Ross SB Peskoe RM Miller N Erho IA Vergara M Ghadessi Z Huang B Gurel BH Park E Davicioni RB Jenkins EA Platz DM Berman EM Schaeffer 《Proceedings of the National Academy of Sciences of the United States of America》2012,109(37):14977-14982
Prostate cancer is the second leading cause of cancer death among United States men. However, disease aggressiveness is varied, with low-grade disease often being indolent and high-grade cancer accounting for the greatest density of deaths. Outcomes are also disparate among men with high-grade prostate cancer, with upwards of 65% having disease recurrence even after primary treatment. Identification of men at risk for recurrence and elucidation of the molecular processes that drive their disease is paramount, as these men are the most likely to benefit from multimodal therapy. We previously showed that androgen-induced expression profiles in prostate development are reactivated in aggressive prostate cancers. Herein, we report the down-regulation of one such gene, Sparcl1, a secreted protein, acidic and rich in cysteine (SPARC) family matricellular protein, during invasive phases of prostate development and regeneration. We further demonstrate a parallel process in prostate cancer, with decreased expression of SPARCL1 in high-grade/metastatic prostate cancer. Mechanistically, we demonstrate that SPARCL1 loss increases the migratory and invasive properties of prostate cancer cells through Ras homolog gene family, member C (RHOC), a known mediator of metastatic progression. By using models incorporating clinicopathologic parameters to predict prostate cancer recurrence after treatment, we show that SPARCL1 loss is a significant, independent prognostic marker of disease progression. Thus, SPARCL1 is a potent regulator of cell migration/invasion and its loss is independently associated with prostate cancer recurrence. 相似文献